Thus, blocking the CXCR4-CXCL12 pathway using this antagonist reduced mast cell infiltration into the skin, tumors and draining lymph nodes, and this subsequently prevents immune suppression and tumor development (149). Here, CXCL12 is linked to neoplasm.